We report somatic mutations of RNF43 in over 18% of colorectal adenocarcinomas and endometrial carcinomas. RNF43 encodes an E3 ubiquitin ligase that negatively regulates Wnt signaling. Truncating mutations of RNF43 are more prevalent in microsatellite-unstable tumors and show mutual exclusivity with inactivating APC mutations in colorectal adenocarcinomas. These results indicate that RNF43 is one of the most commonly mutated genes in colorectal and endometrial cancers.
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The E3 ubiquitin-protein ligase RNF43 negatively regulates the Wnt signaling pathway 1 . Somatic mutations in RNF43 have been associated with heightened sensitivity to compounds that target the Wntspecific acyltransferase porcupine (PORCN) in preclinical models 2 . In parallel, clinical trials of small-molecule porcupine inhibitors (for example, LGK974) are ongoing in Wnt ligand-dependent malignancies (melanoma, pancreatic, breast, head and neck, and colorectal cancers). RNF43 is frequently mutated in pancreatic cystic neoplasms 3 and in <5% of pancreatic carcinomas with acinar differentiation 4 ; however, RNF43 mutations have not been reported in melanoma 5 , breast cancer 6 , or head and neck malignancies 7 . In colorectal cancer, Wnt signaling is more commonly dysregulated through loss-offunction APC mutations 8 , whereas RNF43 has not been reported to be significantly mutated in previous sequencing studies 9, 10 .
Unexpectedly, our whole-exome sequencing of colorectal cancers identified a large number of non-silent somatic mutations in RNF43. DNA isolated from a discovery set of 185 formalin-fixed, paraffin-embedded colorectal tumor and matched normal samples collected from participants in 2 prospective cohort studies, the Nurses' Health Study (NHS) and the Health Professionals FollowUp Study (HPFS) 11 , showed RNF43 mutations in 35 (18.9%) cases (median allelic fraction of 0.23, range of 0.01-0.68) (Supplementary Table 1 ). Frameshift mutations encoding p.Gly659fs and p.Arg117fs constituting insertions or deletions of 1 bp in homopolymeric tracts (microsatellite instability (MSI) loci) of seven and six C•G pairs, respectively, accounted for 41.7% (p.Gly659fs) and 8.3% (p.Arg117fs) of the RNF43 mutations identified (Fig. 1a) . To exclude the possibility that these mutations represented technical artifacts, we validated 31 of the RNF43 mutations (97% of the 32 reactions that had leftover DNA available and achieved coverage of >50× in resequencing or successfully underwent Sanger sequencing) in the mutant tumors and their matched normal tissue ( Supplementary  Fig. 1 and Supplementary Table 1) .
The unexpectedly high frequency of truncating RNF43 mutations in our colorectal tumor cohort contrasted with the paucity of RNF43 mutations reported by previous studies of a comparable scale, including a TCGA (The Cancer Genome Atlas) study of 224 colorectal tumor-normal tissue pairs 9 . We hypothesized that previous studies might have inadvertently filtered out many bona fide RNF43 frameshift events owing to their similarity to the polymerase slip errors that may arise during the massively parallel sequencing process. Therefore, we reanalyzed 222 TCGA colorectal tumornormal exomes (representing all TCGA colorectal exomes available on our local servers in September 2013). Of these, 49 cases (22%) were described in the published TCGA study 9 . We discovered RNF43 mutations with high allelic fraction at a frequency of 17.6% (median allelic fraction of 0.38, range of 0.04-0.77; 48.0% encoding p.Gly659fs and 12% encoding p.Arg117fs). We then orthogonally validated these mutations by examining matched RNA sequencing (RNA-seq) data, additionally confirming mRNA expression of the mutant RNF43 alleles (100% validation rate, 44 of 44 mutations in cases with at least 10-fold coverage at the relevant base pair; Supplementary Table 2) . These results confirmed that RNF43 is mutated at a high frequency in colorectal tumors ( Fig. 1b and Supplementary Table 2 ).
In light of this discovery, we reasoned that inactivating mutations in RNF43 might also have been overlooked in previous whole-exome sequencing studies of endometrial cancer, another Wnt-dependent tumor type in which MSI is common. A reanalysis of all 248 endometrial tumor-normal exome pairs from the published TCGA study 12 RNF43 is frequently mutated in colorectal and endometrial cancers b r i e f c o m m u n i c a t i o n s identified the presence of non-silent RNF43 mutations in 18.1% of cases (median allelic fraction of 0.31, range of 0.04-0.87), with the p.Gly659fs variant accounting for 47.3% and the p.Arg117fs variant accounting for 3.6% of the alterations (Fig. 1c and Supplementary  Table 3) . Matched RNA-seq data orthogonally validated these events (91% validation rate, 20 of 22 mutations in cases with at least 10-fold coverage of the relevant base pair; Supplementary Table 3) .
The high frequency of truncating mutations at this locus (together with a low frequency of synonymous mutations) strongly suggested that RNF43 mutations had undergone positive selection during colorectal and endometrial tumor evolution. To investigate this possibility, we analyzed RNF43 in each tumor exome cohort using InVEx, an algorithm we previously developed to infer the presence of positive selection in tumors with high background mutation rates 5 . InVEx uses the exon/intron mutational distribution at a given locus to determine whether a gene has more mutations of predicted functional consequence than expected under a model of no selection. RNF43 emerged as significantly mutated in all three sample sets (NHS/HPFS colorectal cancer, P = 1.4 × 10 −7 ; TCGA colorectal cancer, P = 4.1 × 10 −10 ; TCGA endometrial cancer, P = 2.0 × 10 −7 ). Furthermore, given the empirical somatic indel rate at exonic homopolymeric tracts of seven C•G pairs in tumors with MSI, RNF43 indels causing p.Gly659fs occurred significantly more often than expected by chance (P < 2.2 × 10 −16 , binomial test; 0.08-0.14% mutation frequency across all exonic 7-bp C•G tracts and 9.2-10.8% mutation frequency for the 7-bp C•G tract in RNF43 causing p.Gly659fs, calculated in tumors with MSI). RNF43 indels causing the p.Gly659fs alteration represented the most recurrent indels at exonic C•G homopolymeric tracts of any length in all three cohorts. Thus, RNF43 mutations apparently conferred a fitness advantage to the colorectal and endometrial cancer cells in which they occurred.
As noted earlier, most RNF43 mutations (73-75% of all nonsilent variants) were truncating events (defined as frameshift indels, nonsense mutations and splice-site mutations), consistent with the previous characterization of RNF43 as a tumor-suppressor gene 1 Table 3 ) harbored at least 2 non-silent RNF43 mutations, in line with the Knudson 2-hit hypothesis for tumor-suppressor genes. We cannot exclude the possibility that the mutations affected the same allele in some two-hit cases, but this seems less likely given the overall loss-of-function pattern.
Given that the RNF43 mutations were predominated by small insertions or deletions in homopolymeric tracts in tumor types with a high prevalence of MSI, we hypothesized that these mutations might be enriched in MSI tumors. Indeed, truncating mutations of RNF43 were statistically linked to the microsatellite instability high (MSI-H) phenotype in both tumor types (P < 2.2 × 10 −16 for colorectal cancer and P < 9.0 × 10 −16 for endometrial cancer, Fisher's exact test; Fig. 2a,b) . Overall, RNF43 was mutated in 79.7% of MSI-H colorectal tumors and 50.7% of MSI-H endometrial tumors (Supplementary Table 4) . This association suggests that mismatch repair deficiency creates a permissive environment for the predominant RNF43 frameshift alterations affecting codons 659 and 117.
Inactivating RNF43 mutations should result in augmented Wnt signaling, owing to increased cell surface abundance of the Wnt receptor Frizzled 1,2 . We thus asked whether any of the significantly mutated Wnt pathway genes displayed a mutually exclusive pattern 13 , should also harbor frequent mutations in RNF43. Indeed, we found that 3 of 37 (8.1%) published stomach cancer exomes 13, 14 had non-silent RNF43 mutations, including a mutation encoding p.Gly659fs. Moreover, while this manuscript was under review, two studies reported RNF43 mutations in gastric cancer 15, 16 . These studies also demonstrated a higher percentage of RNF43 mutations in microsatellite-unstable samples in comparison to microsatellite-stable ones (54.6% versus 4.8% and 33% versus 3% in refs. 15 and 16, respectively). The discovery of multiple tumor types with frequent mutations in RNF43 may have near-term clinical relevance in light of preclinical studies showing that RNF43 mutations render Wnt-driven cancer cells susceptible to pharmacological porcupine inhibition 2 . More generally, these findings suggest that large-scale genomic analyses remain a fruitful means to discover biologically and clinically relevant changes in human cancer.
URLs. CGHub, https://cghub.ucsc.edu/; Indelocator, http://www. broadinstitute.org/cancer/cga/indelocator.
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